ACAD
Price
$20.95
Change
-$0.29 (-1.37%)
Updated
Jul 3 closing price
Capitalization
3.51B
24 days until earnings call
TECH
Price
$53.14
Change
-$0.04 (-0.08%)
Updated
Jul 3 closing price
Capitalization
8.33B
37 days until earnings call
Interact to see
Advertisement

ACAD vs TECH

Header iconACAD vs TECH Comparison
Open Charts ACAD vs TECHBanner chart's image
ACADIA Pharmaceuticals
Price$20.95
Change-$0.29 (-1.37%)
Volume$916.96K
Capitalization3.51B
Bio-Techne
Price$53.14
Change-$0.04 (-0.08%)
Volume$843.09K
Capitalization8.33B
ACAD vs TECH Comparison Chart in %
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. TECH commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and TECH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (ACAD: $20.95 vs. TECH: $53.14)
Brand notoriety: ACAD and TECH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 41% vs. TECH: 36%
Market capitalization -- ACAD: $3.51B vs. TECH: $8.33B
ACAD [@Biotechnology] is valued at $3.51B. TECH’s [@Biotechnology] market capitalization is $8.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileTECH’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • TECH’s FA Score: 1 green, 4 red.
According to our system of comparison, both ACAD and TECH are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 3 TA indicator(s) are bullish while TECH’s TA Score has 5 bullish TA indicator(s).

  • ACAD’s TA Score: 3 bullish, 5 bearish.
  • TECH’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, TECH is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -5.67% price change this week, while TECH (@Biotechnology) price change was +0.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

ACAD is expected to report earnings on Nov 11, 2025.

TECH is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TECH($8.33B) has a higher market cap than ACAD($3.51B). TECH has higher P/E ratio than ACAD: TECH (64.02) vs ACAD (15.29). ACAD YTD gains are higher at: 14.169 vs. TECH (-26.016). TECH has higher annual earnings (EBITDA): 283M vs. ACAD (102M). ACAD has more cash in the bank: 682M vs. TECH (141M). ACAD has less debt than TECH: ACAD (56M) vs TECH (423M). TECH has higher revenues than ACAD: TECH (1.21B) vs ACAD (996M).
ACADTECHACAD / TECH
Capitalization3.51B8.33B42%
EBITDA102M283M36%
Gain YTD14.169-26.016-54%
P/E Ratio15.2964.0224%
Revenue996M1.21B82%
Total Cash682M141M484%
Total Debt56M423M13%
FUNDAMENTALS RATINGS
ACAD vs TECH: Fundamental Ratings
ACAD
TECH
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2680
PRICE GROWTH RATING
1..100
4661
P/E GROWTH RATING
1..100
10042
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECH's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for ACAD (61). This means that TECH’s stock grew somewhat faster than ACAD’s over the last 12 months.

TECH's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ACAD (100). This means that TECH’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's SMR Rating (26) in the Biotechnology industry is somewhat better than the same rating for TECH (80). This means that ACAD’s stock grew somewhat faster than TECH’s over the last 12 months.

ACAD's Price Growth Rating (46) in the Biotechnology industry is in the same range as TECH (61). This means that ACAD’s stock grew similarly to TECH’s over the last 12 months.

TECH's P/E Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for ACAD (100). This means that TECH’s stock grew somewhat faster than ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADTECH
RSI
ODDS (%)
Bearish Trend 4 days ago
64%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
74%
Bearish Trend 4 days ago
64%
Momentum
ODDS (%)
Bearish Trend 4 days ago
65%
Bullish Trend 4 days ago
71%
MACD
ODDS (%)
Bearish Trend 4 days ago
69%
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
70%
Bullish Trend 4 days ago
68%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
75%
Bullish Trend 4 days ago
67%
Advances
ODDS (%)
Bullish Trend 19 days ago
73%
Bullish Trend 5 days ago
70%
Declines
ODDS (%)
Bearish Trend 4 days ago
71%
Bearish Trend 7 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
74%
Bearish Trend 4 days ago
61%
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
60%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DGECX21.390.19
+0.90%
BNY Mellon Global Emerging Mkts - C
ATWCX24.400.17
+0.70%
AB Tax-Managed Wealth Apprec Strat C
JVMRX29.230.19
+0.65%
JHancock Disciplined Value Mid Cap R6
PJDCX18.010.10
+0.56%
PGIM Jennison Rising Dividend C
KGGAX15.11-0.03
-0.20%
Kopernik Global All-Cap A